Results 91 to 100 of about 19,002 (159)

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

Clinical Ophthalmology, 2023
Suthasinee Sinawat,1,2 Suthasinee Hemanak,1 Kwanchanok Chanthowong,1 Supat Sinawat,3 Yosanan Yospaiboon1,2 1Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; 2KKU Eye Center, Khon Kaen University, Khon Kaen ...
Sinawat S, Hemanak S, Chanthowong K, Sinawat S, Yospaiboon Y   +4 more
doaj  

Budgetary impact of adding ziv-aflibercept to a United States health plan formulary as a post-oxaliplatin biologic option for patients with metastatic colorectal cancer (mCRC).

, 2015
765 Background: To assess the economic impact of the availability of ziv-aflibercept for patients with mCRC following disease progression after oxaliplatin, a user-adaptable budget impact model was developed for payers, based on use of 5-fluorouracil ...
Stephen F. Thompson, Ravinder Dhawan, Keith Huff, Edward Drea, Daniel Hennessy   +4 more
core   +1 more source

To laser or not?

Indian Journal of Ophthalmology, 2018
A 64-year-old male patient presented to the clinic with diminished vision in his right eye for the past 2 years. Examination revealed a best-corrected visual acuity (BCVA) of counting fingers at 1 m with a scarred choroidal neovascular membrane (CNVM) in
Vishal Govindhari, Jay Chhablani
doaj   +1 more source

Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

, 2016
4 Background: FOLFOX has RR 53% and PFS 6.8 months in MEGA (CALGB 80403). VEGF inhibition has improved survival in some but not all randomized trials in MEGA.
Charles S. Fuchs, Christopher G. Azzoli, Deborah Schrag, Diane M. F. Savarese, James M. Cleary, Lipika Goyal, Thomas Adam Abrams, Douglas Adam Rubinson, Jennifer A. Chan, Nadine Jackson McCleary, Margaret M. Carey, Gabriel Brooks, Matthew B. Yurgelun, Kimmie Ng, Hui Zheng, Jeffrey A. Meyerhardt, Peter C. Enzinger, Christopher Graham   +17 more
core   +1 more source

Intravitreal Injection of Ziv-Aflibercept in Patient With Refractory Age-Related Macular Degeneration

, 2015
The results of a patient with exudative age-related macular degeneration who received an intravitreal injection of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Paris, France) in the right eye are described.
Eduardo Büchele Rodrigues, Bueno de Moraes, Nilva Simeren [UNIFESP], Nilva Simeren Bueno de Moraes, Oliveira Dias, Joao Rafael de [UNIFESP], Farah, Michel Eid [UNIFESP], Rodrigues, Eduardo Buechele [UNIFESP], Camilla Oliveira Xavier, João Rafael de Oliveira Dias, Carsten Meyer, André Maia, Meyer, Carsten [UNIFESP], Michel Eid Farah, Xavier, Camilla Oliveira [UNIFESP], Maia, Andre [UNIFESP]   +13 more
core   +1 more source

Role of Optical Coherence Tomography-angiography in Diagnosis and Monitoring Activity of Macular Telangiectasia-associated Choroidal Neovascular Membrane

Delhi Journal of Ophthalmology
We report the case of a 62-year-old female diagnosed with Type 2A, Stage 5 macular telangiectasia (MacTel). The right eye showed a scarred choroidal neovascular membrane (CNVM) while the left eye had an active CNVM, confirmed with optical coherence ...
Mohd Azaz Quraishi, Pratik Shenoy, Onkar H. Pirdankar, Amit S. Nene, Pushpanjali Badole, Smitesh Shah   +5 more
doaj   +1 more source

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial. [PDF]

Clin Ophthalmol, 2023
Sinawat S, Hemanak S, Chanthowong K, Sinawat S, Yospaiboon Y.   +4 more
europepmc   +1 more source

Intravitreal injections of ziv-aflibercept: in vitro and in vivo safety

, 2019
Objective: To access the cytotoxicity of two fusion proteins with vascular endothelial growth anti-factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium (RPE) cells and Muller-Glia cells in culture by assessing cell viability post
Andrade, Gabriel Costa De [UNIFESP]
core  

Anti-tumor efficacy of anti-Dll4 (REGN1035) and anti-VEGF (ziv-aflibercept) in a sunitinib resistant RP-R-01 ccRCC patient-derived xenograft model.

, 2014
Mice with established subcutaneous tumors were treated with sunitinib for 4 weeks until tumor tissue was no longer responsive to treatment (tumor volume was ∼6 times that of pretreatment volume).
Mukund Seshadri (659823), Paula Sotomayor (186059), Alshad S. Lalani (659826), Li Shen (110858), Kiersten Marie Miles (659822), Dylan Conroy (659824), Frank Kuhnert (659825), Bryan Gillard (527902), Gavin Thurston (659827), Remi Adelaiye (197585), Roberto Pili (186063), Eric Ciamporcero (155252), Kristopher Attwood (318112)   +12 more
core   +1 more source

Effect of REGN1035 and/or anti-VEGF (sunitinib or ziv-aflibercept) treatment on tumor cell viability.

, 2014
Mice (8 mice/group) implanted with (A, B) RP-R-01 or (C) RP-R-02 tissues were treated with vehicle, sunitinib, or ziv-aflibercept and/or REGN1035. Tumors were harvested, processed, and tissue sections were stained for hematoxylin and eosin.
Mukund Seshadri (659823), Paula Sotomayor (186059), Alshad S. Lalani (659826), Li Shen (110858), Kiersten Marie Miles (659822), Dylan Conroy (659824), Frank Kuhnert (659825), Bryan Gillard (527902), Gavin Thurston (659827), Remi Adelaiye (197585), Roberto Pili (186063), Eric Ciamporcero (155252), Kristopher Attwood (318112)   +12 more
core   +1 more source